Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis
GN Pathak, E Wang, J Dhillon… - Annals of …, 2024 - journals.sagepub.com
Objective: This article reviews clinical trial data that assesses the safety, efficacy, and clinical
application of spesolimab, an interleukin-36 (IL-36) blocker, for the treatment of generalized …
application of spesolimab, an interleukin-36 (IL-36) blocker, for the treatment of generalized …